Literature DB >> 29348460

FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node.

Ga-Hang Lee1,2, Ki-Chun Yoo1, Yoojeong An1, Hae-June Lee3, Minyoung Lee3, Nizam Uddin1,4, Min-Jung Kim5, In-Gyu Kim6, Yongjoon Suh7, Su-Jae Lee8.   

Abstract

Basal type breast cancer is the most aggressive and has mesenchymal features with a high metastatic ability. However, the signaling node that determines the basal type features in breast cancer remains obscure. Here, we report that FYN among SRC family kinases is required for the maintenance of basal type breast cancer subtype. Importantly, FYN enhanced NOTCH2 activation in basal type breast cancer cells through STAT5-mediated upregulation of Jagged-1 and DLL4 NOTCH ligands, thereby contributed to mesenchymal phenotypes. In addition, we found that high levels of FYN persist in basal type breast cancer cells by a positive feedback loop between FYN and STAT5. FYN interacted directly with STAT5 and increased p-STAT5 that further acts as a transcription factor for FYN. Taken together, our findings demonstrate a pivotal role of FYN and its downstream effectors in maintaining the basal type features in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29348460     DOI: 10.1038/s41388-017-0114-y

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

Review 1.  A renaissance for SRC.

Authors:  Timothy J Yeatman
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.

Authors:  Nicholas A Pullen; Brian O Barnstein; Yves T Falanga; Zhengqi Wang; Ryo Suzuki; Tenchee D Lama Tamang; Michele C Khurana; Emily A Harry; Petr Draber; Kevin D Bunting; Kazuya Mizuno; Bridget S Wilson; John J Ryan
Journal:  J Biol Chem       Date:  2011-11-30       Impact factor: 5.157

Review 3.  Treatment for advanced tumors: SRC reclaims center stage.

Authors:  Justin M Summy; Gary E Gallick
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

4.  JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.

Authors:  Adrian Britschgi; Rita Andraos; Heike Brinkhaus; Ina Klebba; Vincent Romanet; Urs Müller; Masato Murakami; Thomas Radimerski; Mohamed Bentires-Alj
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

Review 5.  Stat5 in breast cancer: potential oncogenic activity coincides with positive prognosis for the disease.

Authors:  Itamar Barash
Journal:  Carcinogenesis       Date:  2012-11-16       Impact factor: 4.944

6.  Src: a potential target for the treatment of triple-negative breast cancer.

Authors:  D Tryfonopoulos; S Walsh; D M Collins; L Flanagan; C Quinn; B Corkery; E W McDermott; D Evoy; A Pierce; N O'Donovan; J Crown; M J Duffy
Journal:  Ann Oncol       Date:  2011-02-28       Impact factor: 32.976

7.  Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.

Authors:  Mary E Irwin; Natacha Bohin; Julie L Boerner
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

8.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

9.  GOBO: gene expression-based outcome for breast cancer online.

Authors:  Markus Ringnér; Erik Fredlund; Jari Häkkinen; Åke Borg; Johan Staaf
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis.

Authors:  Salvatore Pece; Michela Serresi; Elisa Santolini; Maria Capra; Esther Hulleman; Viviana Galimberti; Stefano Zurrida; Patrick Maisonneuve; Giuseppe Viale; Pier Paolo Di Fiore
Journal:  J Cell Biol       Date:  2004-10-18       Impact factor: 10.539

View more
  16 in total

Review 1.  Two Sides of the Same Coin: The Role of Developmental pathways and pluripotency factors in normal mammary stem cells and breast cancer metastasis.

Authors:  M U J Oliphant; Deguang Kong; Hengbo Zhou; M T Lewis; H L Ford
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-04-22       Impact factor: 2.673

2.  Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma.

Authors:  Shiva Kant; Pravin Kesarwani; Anthony R Guastella; Praveen Kumar; Stewart F Graham; Katie L Buelow; Ichiro Nakano; Prakash Chinnaiyan
Journal:  Mol Cancer Ther       Date:  2020-05-19       Impact factor: 6.261

Review 3.  Notch-Inflammation Networks in Regulation of Breast Cancer Progression.

Authors:  Yulia Liubomirski; Adit Ben-Baruch
Journal:  Cells       Date:  2020-06-28       Impact factor: 6.600

Review 4.  Moving Breast Cancer Therapy up a Notch.

Authors:  Erik W J Mollen; Jonathan Ient; Vivianne C G Tjan-Heijnen; Liesbeth J Boersma; Lucio Miele; Marjolein L Smidt; Marc A G G Vooijs
Journal:  Front Oncol       Date:  2018-11-20       Impact factor: 6.244

5.  Genetic interactions between ANLN and KDR are prognostic for breast cancer survival.

Authors:  Xiaofeng Dai; Xiao Chen; Olivier Hakizimana; Yi Mei
Journal:  Oncol Rep       Date:  2019-09-24       Impact factor: 3.906

6.  Linc00514 promotes breast cancer metastasis and M2 polarization of tumor-associated macrophages via Jagged1-mediated notch signaling pathway.

Authors:  Sifeng Tao; Qiang Chen; Chen Lin; Haiying Dong
Journal:  J Exp Clin Cancer Res       Date:  2020-09-17

Review 7.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

8.  TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer.

Authors:  María Paz Saldías; Diego Maureira; Octavio Orellana-Serradell; Ian Silva; Boris Lavanderos; Pablo Cruz; Camila Torres; Mónica Cáceres; Oscar Cerda
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

9.  CBNA: A control theory based method for identifying coding and non-coding cancer drivers.

Authors:  Vu V H Pham; Lin Liu; Cameron P Bracken; Gregory J Goodall; Qi Long; Jiuyong Li; Thuc D Le
Journal:  PLoS Comput Biol       Date:  2019-12-02       Impact factor: 4.475

10.  FYN promotes gastric cancer metastasis by activating STAT3-mediated epithelial-mesenchymal transition.

Authors:  Jie Yu; ZhiJun Zhou; ZheWei Wei; Jing Wu; Jun OuYang; WeiBin Huang; YuLong He; ChangHua Zhang
Journal:  Transl Oncol       Date:  2020-08-04       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.